Metabolic syndrome

Source: Wikipedia, the free encyclopedia.
Metabolic syndrome
Other namesDysmetabolic syndrome X
polycystic ovarian syndrome, erectile dysfunction, acanthosis nigricans
Part of a series on
Human body weight
General concepts
Medical concepts
Measurements
Related conditions
Obesity-associated morbidity
Management of obesity
Social aspects

Metabolic syndrome is a clustering of at least three of the following five medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL).

Metabolic syndrome is associated with the risk of developing

type 2 diabetes.[1] In the U.S., about 25% of the adult population has metabolic syndrome, a proportion increasing with age, particularly among racial and ethnic minorities.[2][3]

Insulin resistance, metabolic syndrome, and prediabetes are closely related to one another and have overlapping aspects. The syndrome is thought to be caused by an underlying disorder of energy utilization and storage, but the cause of the syndrome is an area of ongoing medical research. Researchers debate whether a diagnosis of metabolic syndrome implies differential treatment or increases risk of cardiovascular disease beyond what is suggested by the sum of its individual components.[4]

Signs and symptoms

The key sign of metabolic syndrome is

polycystic ovarian syndrome in women and erectile dysfunction in men; and acanthosis nigricans.[6]

Neck circumference

Neck circumference has been used as a surrogate simple and reliable index to indicate upper-body subcutaneous fat accumulation. Neck circumference of more than 40.25 cm (15.85 in) for men and more than 35.75 cm (14.07 in) for women are considered high-risk for metabolic syndrome. Persons with large neck circumferences have a more-than-double risk of metabolic syndrome.[7] In adults with overweight/obesity, clinically significant weight loss may protect against COVID-19[8] and neck circumference has been associated with the risk of being mechanically ventilated in COVID-19 patients, with a 26% increased risk for each centimeter increase in neck circumference.[9] Moreover, hospitalized COVID-19 patients with a "large neck phenotype" on admission had a more than double risk of death.[10]

Complications

Metabolic syndrome can lead to several serious and chronic complications, including

nonalcoholic fatty liver disease.[11]

Furthermore, metabolic syndrome is associated with a significantly increased risk of surgical complications across most types of surgery in a 2023 systematic review and meta-analysis of over 13 million individuals.[12]

Causes

The mechanisms of the complex pathways of metabolic syndrome are under investigation. The

risk factors are diet (particularly sugar-sweetened beverage consumption),[13] genetics,[14][15][16][17] aging, sedentary behavior[18] or low physical activity,[19][20] disrupted chronobiology/sleep,[21] mood disorders/psychotropic medication use,[22][23] and excessive alcohol use.[24] The pathogenic role played in the syndrome by the excessive expansion of adipose tissue occurring under sustained overeating, and its resulting lipotoxicity was reviewed by Vidal-Puig.[25]

There is debate regarding whether obesity or insulin resistance is the cause of the metabolic syndrome or if they are consequences of a more far-reaching metabolic derangement. Markers of systemic

tumor necrosis factor-alpha (TNF-α), and others. Some have pointed to a variety of causes, including increased uric acid levels caused by dietary fructose.[26][27][28]

Research shows that Western diet habits are a factor in the development of metabolic syndrome, with high consumption of food that is not biochemically suited to humans.[29][page needed] Weight gain is associated with metabolic syndrome. Rather than total adiposity, the core clinical component of the syndrome is visceral and/or ectopic fat (i.e., fat in organs not designed for fat storage) whereas the principal metabolic abnormality is insulin resistance.[30] The continuous provision of energy via dietary carbohydrate, lipid, and protein fuels, unmatched by physical activity/energy demand, creates a backlog of the products of mitochondrial oxidation, a process associated with progressive mitochondrial dysfunction and insulin resistance.[citation needed]

Stress

Recent research indicates prolonged

visceral adiposity, insulin resistance, dyslipidemia and hypertension, with direct effects on the bone, causing "low turnover" osteoporosis.[32] HPA-axis dysfunction may explain the reported risk indication of abdominal obesity to cardiovascular disease (CVD), type 2 diabetes and stroke.[33] Psychosocial stress is also linked to heart disease.[34]

Obesity

Central obesity is a key feature of the syndrome, as both a sign and a cause, in that the increasing adiposity often reflected in high

waist circumference may both result from and contribute to insulin resistance. However, despite the importance of obesity, affected people who are of normal weight may also be insulin-resistant and have the syndrome.[35]

Sedentary lifestyle

Physical inactivity is a predictor of CVD events and related mortality. Many components of metabolic syndrome are associated with a sedentary lifestyle, including increased adipose tissue (predominantly central); reduced HDL cholesterol; and a trend toward increased triglycerides, blood pressure, and glucose in the genetically susceptible. Compared with individuals who watched television or videos or used their computers for less than one hour daily, those who carried out these behaviors for greater than four hours daily have a twofold increased risk of metabolic syndrome.[35]

Aging

Metabolic syndrome affects 60% of the U.S. population older than age 50. With respect to that demographic, the percentage of women having the syndrome is higher than that of men. The age dependency of the syndrome's prevalence is seen in most populations around the world.[35]

Diabetes mellitus type 2

Main articles:
Diabetes mellitus type 2

The metabolic syndrome quintuples the risk of type 2 diabetes mellitus. Type 2 diabetes is considered a complication of metabolic syndrome.[1] In people with impaired glucose tolerance or impaired fasting glucose, presence of metabolic syndrome doubles the risk of developing type 2 diabetes.[36] It is likely that prediabetes and metabolic syndrome denote the same disorder, defining it by the different sets of biological markers.[citation needed]

The presence of metabolic syndrome is associated with a higher prevalence of CVD than found in people with type 2 diabetes or

impaired glucose tolerance without the syndrome.[35] Hypoadiponectinemia has been shown to increase insulin resistance[37] and is considered to be a risk factor for developing metabolic syndrome.[38]

Coronary heart disease

The approximate prevalence of the metabolic syndrome in people with

cardiac rehabilitation and changes in lifestyle (e.g., nutrition, physical activity, weight reduction, and, in some cases, drugs), the prevalence of the syndrome can be reduced.[35]

Lipodystrophy

highly active antiretroviral therapy) forms of lipodystrophy may give rise to severe insulin resistance and many of metabolic syndrome's components.[35]

Rheumatic diseases

There is research that associates comorbidity with rheumatic diseases. Both psoriasis and psoriatic arthritis have been found to be associated with metabolic syndrome.[39]

Chronic obstructive pulmonary disease

Metabolic syndrome is seen to be a comorbidity in up to 50 percent of those with chronic obstructive pulmonary disease (COPD). It may pre-exist or may be a consequence of the lung pathology of COPD.[40]

Pathophysiology

It is common for there to be a development of

PAI-1). TNF-α has been shown to cause the production of inflammatory cytokines and also possibly trigger cell signaling by interaction with a TNF-α receptor that may lead to insulin resistance.[41] An experiment with rats fed a diet with 33% sucrose has been proposed as a model for the development of metabolic syndrome. The sucrose first elevated blood levels of triglycerides, which induced visceral fat and ultimately resulted in insulin resistance. The progression from visceral fat to increased TNF-α to insulin resistance has some parallels to human development of metabolic syndrome. The increase in adipose tissue also increases the number of immune cells, which play a role in inflammation. Chronic inflammation contributes to an increased risk of hypertension, atherosclerosis and diabetes.[42]

The involvement of the endocannabinoid system in the development of metabolic syndrome is indisputable.[43][44][45] Endocannabinoid overproduction may induce reward system dysfunction[44] and cause executive dysfunctions (e.g., impaired delay discounting), in turn perpetuating unhealthy behaviors.[medical citation needed] The brain is crucial in development of metabolic syndrome, modulating peripheral carbohydrate and lipid metabolism.[43][44]

Metabolic syndrome can be induced by overfeeding with sucrose or fructose, particularly concomitantly with high-fat diet.

fatty acid amide hydrolase (FAAH) mediates the metabolism of anandamide into arachidonic acid.[47][45] Anandamide can also be produced from N-acylphosphatidylethanolamine via several pathways.[45] Anandamide and 2-AG can also be hydrolized into arachidonic acid, potentially leading to increased eicosanoid synthesis.[45]

Diagnosis

NCEP

As of 2023, the U.S. National Cholesterol Education Program Adult Treatment Panel III (2001) continues to be the most widely-used clinical definition.[4] It requires at least three of the following:[48]

  • Central obesity: waist circumference ≥ 102 cm or 40 inches (male), ≥ 88 cm or 35 inches(female)
  • Dyslipidemia: TG ≥ 1.7 mmol/L (150 mg/dl)
  • Dyslipidemia: HDL-C < 40 mg/dL (male), < 50 mg/dL (female)
  • Blood pressure ≥ 130/85 mmHg (or treated for hypertension)
  • Fasting plasma glucose ≥ 6.1 mmol/L (110 mg/dl)

2009 Interim Joint Statement

The International Diabetes Federation Task Force on Epidemiology and Prevention; the National Heart, Lung, and Blood Institute; the American Heart Association; the World Heart Federation; the International Atherosclerosis Society; and the International Association for the Study of Obesity published an interim joint statement to harmonize the definition of the metabolic syndrome in 2009.[49] According to this statement, the criteria for clinical diagnosis of the metabolic syndrome are three or more of the following:

  • Elevated waist circumference with population- and country-specific definitions
  • Elevated triglycerides (≥ 150 mg/dL (1.7 mmol/L))
  • Reduced HDL-C (≤40 mg/dL (1.0 mmol/L) in males, ≤50 mg/dL (1.3 mmol/L) in females)
  • Elevated blood pressure (systolic ≥130 and/or diastolic ≥85 mm Hg)
  • Elevated fasting glucose (≥100 mg/dL (5.55 mmol/L)[49]

This definition recognizes that the risk associated with a particular waist measurement will differ in different populations. However, for international comparisons and to facilitate the etiology, the organizations agree that it is critical that a commonly agreed-upon set of criteria be used worldwide, with agreed-upon cut points for different ethnic groups and sexes. There are many people in the world of mixed ethnicity, and in those cases, pragmatic decisions will have to be made. Therefore, an international criterion of overweight may be more appropriate than ethnic specific criteria of abdominal obesity for an anthropometric component of this syndrome which results from an excess lipid storage in adipose tissue, skeletal muscle and liver.[49]

The report notes that previous definitions of the metabolic syndrome by the International Diabetes Federation[50] (IDF) and the revised National Cholesterol Education Program (NCEP) are very similar, and they identify individuals with a given set of symptoms as having metabolic syndrome. There are two differences, however: the IDF definition states that if body mass index (BMI) is greater than 30 kg/m2, central obesity can be assumed, and waist circumference does not need to be measured. However, this potentially excludes any subject without increased waist circumference if BMI is less than 30. Conversely, the NCEP definition indicates that metabolic syndrome can be diagnosed based on other criteria. Also, the IDF uses geography-specific cut points for waist circumference, while NCEP uses only one set of cut points for waist circumference regardless of geography.[citation needed]

WHO

The World Health Organization (1999)[51] requires the presence of any one of diabetes mellitus, impaired glucose tolerance, impaired fasting glucose or insulin resistance, AND two of the following:

  • Blood pressure ≥ 140/90 mmHg
  • Dyslipidemia: triglycerides (TG) ≥ 1.695 mmol/L and HDL cholesterol ≤ 0.9 mmol/L (male), ≤ 1.0 mmol/L (female)
  • Central obesity: waist:hip ratio > 0.90 (male); > 0.85 (female), or BMI > 30 kg/m2
  • Microalbuminuria: urinary albumin excretion ratio ≥ 20 µg/min or albumin:creatinine ratio ≥ 30 mg/g

EGIR

The European Group for the Study of Insulin Resistance (1999) requires that subjects have insulin resistance (defined for purposes of clinical practivality as the top 25% of the fasting insulin values among nondiabetic individuals) AND two or more of the following:[52]

  • Central obesity: waist circumference ≥ 94 cm or 37 inches (male), ≥ 80 cm or 31.5 inches (female)
  • Dyslipidemia: TG ≥ 2.0 mmol/L (177 mg/dL) and/or HDL-C < 1.0 mmol/L (38.61 mg/dL) or treated for dyslipidemia
  • Blood pressure ≥ 140/90 mmHg or antihypertensive medication
  • Fasting plasma glucose ≥ 6.1 mmol/L (110 mg/dL)

Cardiometabolic index

The Cardiometabolic index (CMI) is a tool used to calculate risk of type 2 diabetes, non-alcoholic fatty liver disease,[53] and metabolic issues. It is based on calculations from waist-to-height ratio and triglycerides-to-HDL cholesterol ratio.[54]

CMI can also be used for finding connections between cardiovascular disease and erectile dysfunction.[55] When following an anti inflammatory diet (low-glycemic carbohydrates, fruits, vegetables, fish, less red meat and processed foods) the markers may drop resulting in a significant reduction in body weight and adipose tissue.[56]

Other

High-sensitivity C-reactive protein has been developed and used as a marker to predict coronary vascular diseases in metabolic syndrome, and it was recently used as a predictor for nonalcoholic fatty liver disease (steatohepatitis) in correlation with serum markers that indicated lipid and glucose metabolism.[57] Fatty liver disease and steatohepatitis can be considered manifestations of metabolic syndrome, indicative of abnormal energy storage as fat in ectopic distribution. Reproductive disorders (such as polycystic ovary syndrome in women of reproductive age), and erectile dysfunction or decreased total testosterone (low testosterone-binding globulin) in men can be attributed to metabolic syndrome.[58]

Prevention

Various strategies have been proposed to prevent the development of metabolic syndrome. These include increased

International Obesity Taskforce states that interventions on a sociopolitical level are required to reduce development of the metabolic syndrome in populations.[61]

The

randomized controlled trials said that, in the short term, a paleolithic nutritional pattern improved three of five measurable components of the metabolic syndrome in participants with at least one of the components.[64]

Management

Medications

Generally, the individual disorders that compose the metabolic syndrome are treated separately.[65] Diuretics and ACE inhibitors may be used to treat hypertension. Various cholesterol medications may be useful if LDL cholesterol, triglycerides, and/or HDL cholesterol is abnormal.[citation needed]

Diet

Dietary carbohydrate restriction reduces blood glucose levels, contributes to weight loss, and reduces the use of several medications that may be prescribed for metabolic syndrome.[66]

Epidemiology

Main article: Epidemiology of metabolic syndrome

Approximately 20–25 percent of the world's adult population has the cluster of risk factors that is metabolic syndrome.[50] In 2000, approximately 32% of U.S. adults had metabolic syndrome.[67][68] In more recent years that figure has climbed to 34%.[68][69]

In young children, there is no consensus on how to measure metabolic syndrome since age-specific cut points and reference values that would indicate "high risk" have not been well established.[70] A continuous cardiometabolic risk summary score is often used for children instead of a dichotomous measure of metabolic syndrome.[71]

Other conditions[72] and specific microbiome diversity[73] seems to be associated with metabolic syndrome, with certain-degree of gender-specificity.[74]

History

In 1921, Joslin first reported the association of diabetes with hypertension and hyperuricemia.[75] In 1923, Kylin reported additional studies on the above triad.[76] In 1947, Vague observed that upper body obesity appeared to predispose to diabetes, atherosclerosis, gout and calculi.[77] In the late 1950s, the term metabolic syndrome was first used.

In 1967, Avogadro, Crepaldi and coworkers described six moderately obese people with diabetes, hypercholesterolemia, and marked hypertriglyceridemia, all of which improved when the affected people were put on a hypocaloric, low-carbohydrate diet.[78] In 1977, Haller used the term metabolic syndrome for associations of obesity, diabetes mellitus,

hepatic steatosis when describing the additive effects of risk factors on atherosclerosis.[79]
The same year, Singer used the term for associations of obesity, gout, diabetes mellitus, and hypertension with hyperlipoproteinemia.[80] In 1977 and 1978, Gerald B. Phillips developed the concept that risk factors for
sex hormones.[81][82]
In 1988, in his
Gerald M. Reaven proposed insulin resistance as the underlying factor and named the constellation of abnormalities syndrome X. Reaven did not include abdominal obesity, which has also been hypothesized as the underlying factor, as part of the condition.[83]

See also

References

  1. ^ a b "Metabolic syndrome". Mayo Clinic. Retrieved 10 Sep 2020.
  2. PMID 24819559
    .
  3. PMID 23810877
    .
  4. ^ a b Anagnostis, Panagiotis (November 30, 2023). "Metabolic Syndrome". BMJ Best Practice. Retrieved 30 December 2023.
  5. ^ "Metabolic Syndrome". Diabetes.co.uk. 15 January 2019.
  6. PMID 29106690
    .
  7. PMID 37456431
    .
  8. PMID 37833678
    .
  9. PMID 32484298
    .
  10. PMID 34940406
    .
  11. ^ "Metabolic syndrome - Symptoms and causes". Mayo Clinic. Retrieved 2022-03-31.
  12. PMID 37916943
    .
  13. PMID 20693348
    .
  14. S2CID 24558150
    .
  15. S2CID 26582450
    .
  16. S2CID 8974554
    .
  17. PMID 7550538
    .
  18. PMID 22514690
    .
  19. ^
    S2CID 25598917
    .
  20. S2CID 5271746
    .
  21. PMID 23890470
    .
  22. S2CID 206253750
    .
  23. PMID 23361837
    .
  24. PMID 24315622
    .
  25. PMID 24490226
    .
  26. PMID 16234313
    .
  27. S2CID 23659634
    .
  28. PMID 2497634
    .
  29. PMID 22351884
    .
  30. PMID 27178543
    .
  31. S2CID 22734016
    .
  32. PMID 12377295
    .
  33. S2CID 20336259
    .
  34. S2CID 5992769
    .
  35. ^
    ISBN 978-0-07-147692-8.[page needed
    ]
  36. PMID 22895669
    .
  37. S2CID 20799218
    .
  38. PMID 19258676
    .
  39. ^ Quilon III A, Brent L (2010). "The primary care physician's guide to inflammatory arthritis: diagnosis". The Journal of Musculoskeletal Medicine. 27: 223–31.
  40. PMID 30822464
    .
  41. S2CID 58332116
    .
  42. Wadsworth Cengage Learning
    : Belmont, CA
  43. ^
    PMID 26408168
    . The endocannabinoid system (ECS) is known to exert regulatory control on essentially every aspect related to the search for, and the intake, metabolism and storage of calories, and consequently it represents a potential pharmacotherapeutic target for obesity, diabetes and eating disorders. ... recent research in animals and humans has provided new knowledge on the mechanisms of actions of the ECS in the regulation of eating behavior, energy balance, and metabolism. In this review, we discuss these recent advances and how they may allow targeting the ECS in a more specific and selective manner for the future development of therapies against obesity, metabolic syndrome, and eating disorders.
  44. ^
    PMID 18155257
    . The etiology of many appetitive disorders is characterized by a pathogenic component of reward-supported craving, be it for substances of abuse (including alcohol and nicotine) or food. Such maladies affect large numbers of people as prevalent socioeconomic and healthcare burdens. Yet in most instances drugs for their safe and effective pharmacotherapeutic management are lacking despite the attendant medical needs, collateral adverse physical and psychological effects, and enormous global market potential. The endocannabinoid signaling system plays a critical role in motivational homeostasis as a conduit for reward stimuli and a positive modulator of brain reward circuits. Endocannabinoid-system hyperactivity through CB1 receptor transmission is considered contributory to a range of appetitive disorders and, hence, is a major focus of contemporary pharmaceutical research.
  45. ^
    S2CID 206999921
    .
  46. S2CID 20966659
    .
  47. S2CID 4341716
    .
  48. PMID 11368702
    .
  49. ^
    PMID 19805654
    .
  50. ^ a b Alberti G, Zimmet P, Shaw J (2006). Grundy SM (ed.). IDF Consensus Worldwide Definition of the Metabolic Syndrome (PDF) (Report). Brussels, Belgium: International Diabetes Federation. Archived from the original on 2012-09-16.
  51. ^ Alberti KG, et al. (1999). "Definition, Diagnosis, and Classification of Diabetes Mellitus and its Complications" (PDF). World Health Organization. pp. 32–33. Archived from the original (PDF) on 21 August 2014. Retrieved 25 March 2013.
  52. PMID 10342346
    .
  53. S2CID 251912707
    .
  54. PMID 35055447
    .
  55. PMID 30798136
    .
  56. PMID 36235638
    .
  57. S2CID 1193178
    .
  58. PMID 20870782
    .
  59. PMID 17332786
    .
  60. PMID 17332784
    .
  61. S2CID 36797932
    .
  62. PMID 17630368
    .
  63. PMID 17413097
    .
  64. PMID 26269362
    .
  65. PMID 26816492
    .
  66. PMID 25287761
    .
  67. S2CID 5145131
    .
  68. ^
    PMID 15451914
    .
  69. PMID 20889854
    .
  70. S2CID 52291692
    .
  71. PMID 30169210
    .
  72. PMID 29106690
    .
  73. S2CID 256744684
    .
  74. PMID 37038173
    .
  75. doi:10.1001/jama.1921.02630020001001
    .
  76. ^ Kylin E (1923). "[Studies of the hypertension-hyperglycemia-hyperuricemia syndrome]". Zentralbl Inn Med (in German). 44: 105–127.
  77. ^ Vague J (1947). "La diffférenciacion sexuelle, facteur déterminant des formes de l'obésité". Presse Med. 30: 339–340.
  78. S2CID 25839940
    .
  79. PMID 883354
    .
  80. PMID 906591
    .
  81. PMID 356599
    .
  82. PMID 193114
    .
  83. PMID 3056758
    .
Retrieved from "https://en.wikipedia.org/w/index.php?title=Metabolic_syndrome&oldid=1220202903"